This Article Free Full Text (Free PDF) Free References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Gibson, J. P. Articles by Newberne, J. W. Search for Related Content PubMed PubMed Citation Articles by Gibson, J. P. Articles by Newberne, J. W. Social Bookmarking                         What's this?

Chronic Toxicity Studies with Vigabatrin, A GABA-Transaminase Inhibitor

Merrell Dow Research Institute, Merrell Dow Pharmaceuticals Inc., Cincinnati, Ohio 45215

John T. Yarrington

Merrell Dow Research Institute, Merrell Dow Pharmaceuticals Inc., Cincinnati, Ohio 45215

David E. Loudy

Merrell Dow Research Institute, Merrell Dow Pharmaceuticals Inc., Cincinnati, Ohio 45215

Clifford G. Gerbig

Merrell Dow Research Institute, Merrell Dow Pharmaceuticals Inc., Cincinnati, Ohio 45215

Gail H. Hurst

Merrell Dow Research Institute, Merrell Dow Pharmaceuticals Inc., Cincinnati, Ohio 45215

James W. Newberne

Merrell Dow Research Institute, Merrell Dow Pharmaceuticals Inc., Cincinnati, Ohio 45215

The GABA-transaminase inhibitor, vigabatrin, has been shown to have a rather low degree of acute toxicity in several animal species. Oral administration of the drug at 1,000 mg/kg/day for 2-4 weeks caused decreased food consumption and weight loss with resultant prostration and death in both rats and dogs. Dosages of 200 mg/kg/day were tolerated for a year without clinical signs in dogs, although rats suffered reduced weight gains and convulsions after 3-4 months when given the drug in the diet. The convulsions continued to occur frequently throughout the one-yr study, but abated 3-4 months after cessation of treatment. The only consistent histopathologic evidence of toxicity in rats and dogs has been the finding of intramyelinic edema (microvacuolation) in the brain, most notably in certain areas of white matter (cerebellum, reticular formation and optic tract in rats and columns of fornix and optic tract in dogs). No lesions were found in the spinal cord or peripheral nervous system. It took several weeks for the microvacuolation to develop, even at high dosages, but it did not continue to progress thereafter, even though a slight effect was noted at dosages as low as 30-50 mg/kg/day after one yr of treatment. The intramyelinic edemia disappeared within a few weeks after treatment was withdrawn. No residual effects were observed in dogs, whereas rats exhibited swollen axons and microscopic mineralized bodies in the cerebellum. Monkeys exhibited no adverse clinical effects except for occasional loose stools at 300 mg/kg/day. After 16 months of oral treatment at 300 mg/kg/day any suggestion of intramyelinic edema was considered to be equivocal, and there was no evidence of any effect in the 50 or 100 mg/kg/day monkeys after 6 yr of treatment. Higher doses caused chronic diarrhea, thus limiting the dosage in this species. Vigabatrin was shown to be well absorbed in rat, dog and man, whereas dose-limited absorption occurred in the monkey. Metabolism is practically nil in all 4 species and the primary elimination pathway is by glomerular filtration. Because vigabatrin is an irreversible inhibitor of GABA-transaminase and the enzyme has a slow turnover rate, plasma levels of the drug are not indicative of its pharmacologic activity. For this reason cerebrospinal fluid levels of GABA and vigabatrin were evaluated, with considerable species differences being noted. The significance of these differences in relation to the differences in toxic response is discussed.

Key Words: -vinyl GABA • GVG • intramyelinic edema • rat • dog • monkey

Toxicologic Pathology, Vol. 18, No. 2, 225-238 (1990)
DOI: 10.1177/019262339001800201


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. Horton, M. Rafay, and M. R. Del Bigio Pathological Evidence of Vacuolar Myelinopathy in a Child Following Vigabatrin Administration J Child Neurol, December 1, 2009; 24(12): 1543 - 1546. [Abstract] [PDF]

				J. T. Yarrington, J. P. Gibson, J. E. Dillberger, G. Hurst, B. Lippert, N. M. Sussman, W. E. Heydorn, and R. J. Marler Sequential Neuropathology of Dogs Treated with Vigabatrin, a GABA-Transaminase Inhibitor Toxicol Pathol, September 1, 1993; 21(5): 480 - 489. [Abstract] [PDF]

				J. Mumford and O. Dulac Vigabatrin: A New Antiepileptic Medication J Child Neurol, October 1, 1991; 6(2_suppl): 2S3 - 2S6. [PDF]

				D.J. Cannon, W.H. Butler, J.P. Mumford, and P.J. Lewis Neuropathologic Findings in Patients Receiving Long-Term Vigabatrin Therapy for Chronic Intractable Epilepsy J Child Neurol, October 1, 1991; 6(2_suppl): 2S17 - 2S24. [Abstract] [PDF]